SK Bioscience Wins First UNICEF Contract...Expands Global Public Procurement Market
Selected as Sole Supplier for the Southern Hemisphere and Major Supplier for the Northern Hemisphere
SK Bioscience is accelerating its expansion into overseas markets after winning a bid to supply vaccines for international organizations' public procurement. By combining profitability and public value in its business model, the company is further strengthening its competitiveness in the global health sector.
On June 2, SK Bioscience announced that it has been designated by UNICEF as a supplier of influenza vaccines for 2026 and has begun shipping doses to countries in the Southern Hemisphere. Starting in September, the company will also begin supplying vaccines to the Northern Hemisphere, and plans to deliver approximately 640,000 doses of influenza vaccine sequentially within the year, aligning with each country's vaccination schedule.
The countries receiving supply include Laos, Myanmar, and Fiji in the Southern Hemisphere, followed by Ethiopia, Lebanon, Albania, and Palestine in the Northern Hemisphere. Notably, SK Bioscience has been selected as the sole supplier for UNICEF’s Southern Hemisphere quota, providing the entire volume for that season. For the Northern Hemisphere, the company has been selected as a major supplier and will provide a significant quantity. Through this, SK Bioscience will establish a year-round production system and accumulate operational experience in responding to varying seasonal and vaccination demands.
This contract is significant as it covers both the Southern and Northern Hemispheres and marks SK Bioscience's first collaboration with UNICEF. The company has now diversified its supply channels, adding UNICEF to its existing partnership with PAHO (Pan American Health Organization), thereby securing a supply base that encompasses the two largest global public procurement markets. In particular, by participating in public procurement projects that improve vaccine accessibility for countries vulnerable to infectious diseases, SK Bioscience has established a business model that achieves both stable revenue generation and the realization of social value.
SK Bioscience's influenza vaccine, 'Skyscellflu,' has demonstrated excellent immunogenicity and safety through Phase 3 clinical trials, and, based on this, became the world’s first cell-culture influenza vaccine to obtain WHO PQ (prequalification) certification. Additionally, the vaccine’s effectiveness has been further verified through Real World Evidence (RWE) studies that analyzed its actual use in the field. The cell-culture method is known for its low risk of virus mutation during production, resulting in a high match rate with circulating viruses. The shorter production period also enables rapid vaccine supply during infectious disease crises such as pandemics.
To date, SK Bioscience has expanded its business opportunities in the global health sector through supplying influenza vaccines via PAHO, as well as collaborations with the International Vaccine Institute (IVI) and the Coalition for Epidemic Preparedness Innovations (CEPI). These experiences have enhanced the company’s ability to meet diverse regulatory requirements and supply conditions across different countries, providing a foundation for further expansion into the international procurement market.
Jae-Yong Ahn, CEO of SK Bioscience, commented, "This first contract with UNICEF is a meaningful achievement that further expands our entry into the global public procurement market. Based on a business model that considers both profitability and public value, we will continue to strengthen cooperation with international organizations to contribute to infectious disease response and public health improvement worldwide."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, SK Bioscience is also accelerating the global approval of its major products, including its influenza vaccine and the varicella vaccine 'Skyvaricella.' Recently, the company obtained product approval for 'Skyvaricella' in Vietnam and secured new approval for its influenza vaccine in Moldova, Eastern Europe. In addition, SK Bioscience continues to broaden its global business foundation by obtaining product approvals for its key products in several countries, including Thailand, Malaysia, Mongolia, Pakistan, and Chile.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.